2013 - Fellow of the Royal Society of New Zealand
Andrew W. Roberts focuses on Cancer research, Leukemia, Venetoclax, Immunology and Internal medicine. His Cancer research research is multidisciplinary, incorporating perspectives in Mutation, Apoptosis, Signal transduction and Molecular biology. His studies in Leukemia integrate themes in fields like breakpoint cluster region, Navitoclax, In vivo and Imatinib mesylate.
His studies deal with areas such as Cancer, Refractory Chronic Lymphocytic Leukemia, Pharmacology and Rituximab as well as Venetoclax. His research in Immunology intersects with topics in Progenitor cell and SOCS3. His Internal medicine study combines topics from a wide range of disciplines, such as Endocrinology, Oncology and B cell.
His primary areas of investigation include Internal medicine, Venetoclax, Cancer research, Immunology and Oncology. His Internal medicine research integrates issues from Gastroenterology and Surgery. In his study, which falls under the umbrella issue of Venetoclax, Myeloid is strongly linked to Myeloid leukemia.
His work deals with themes such as Apoptosis, B cell, Lymphoma, Leukemia and MCL1, which intersect with Cancer research. His Leukemia research is multidisciplinary, relying on both Cancer, Navitoclax, In vivo, Mutation and Pharmacology. The various areas that Andrew W. Roberts examines in his Immunology study include Progenitor cell and Haematopoiesis.
His scientific interests lie mostly in Venetoclax, Internal medicine, Cancer research, Oncology and Chronic lymphocytic leukemia. Leukemia covers Andrew W. Roberts research in Venetoclax. In general Internal medicine, his work in Hematology, Rituximab and Neutropenia is often linked to In patient linking many areas of study.
He combines subjects such as Mutation, Tyrosine kinase, Bruton's tyrosine kinase, B cell and MCL1 with his study of Cancer research. His Oncology study integrates concerns from other disciplines, such as Relapsed refractory and Lymphocytic leukaemia. His study in Chronic lymphocytic leukemia is interdisciplinary in nature, drawing from both Hematopoietic stem cell transplantation, Targeted therapy, Fludarabine and Single agent.
His primary areas of investigation include Venetoclax, Internal medicine, Cancer research, Leukemia and Oncology. The subject of his Venetoclax research is within the realm of Chronic lymphocytic leukemia. His work in Internal medicine tackles topics such as Neoplasm which are related to areas like Follicular lymphoma, Mutation and Missense mutation.
His work investigates the relationship between Cancer research and topics such as Mutation that intersect with problems in Plasma protein binding, Apoptosis, Mutant and Binding site. The study incorporates disciplines such as Drug resistance and B cell in addition to Leukemia. Andrew W. Roberts studied Myeloid leukemia and Myeloid that intersect with Myeloid Cell Leukemia Sequence 1 Protein, Bone marrow and MCL1.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Andrew J Souers;Joel D Leverson;Erwin R Boghaert;Scott L Ackler.
Nature Medicine (2013)
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
Andrew W. Roberts;Matthew S. Davids;John M. Pagel;Brad S. Kahl.
The New England Journal of Medicine (2016)
The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.
Mark F. van Delft;Andrew H. Wei;Kylie D. Mason;Kylie D. Mason;Cassandra J. Vandenberg.
Cancer Cell (2006)
Programmed Anuclear Cell Death Delimits Platelet Life Span
Kylie D Mason;Marina Carpinelli;Jamie I Fletcher;Janelle Elyse Collinge.
SOCS3 negatively regulates IL-6 signaling in vivo.
Ben A Croker;Danielle L Krebs;Jian-Guo Zhang;Sam Wormald.
Nature Immunology (2003)
Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease
Andrew W. Roberts;John F. Seymour;John F. Seymour;Jennifer R. Brown;William G. Wierda.
Journal of Clinical Oncology (2012)
The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models
András Kotschy;Zoltán Szlavik;James Murray;James Davidson.
Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study
Stephan Stilgenbauer;Barbara Eichhorst;Johannes Schetelig;Steven Coutre.
Lancet Oncology (2016)
The genomic landscape of hypodiploid acute lymphoblastic leukemia
Linda Holmfeldt;Lei Wei;Ernesto Diaz-Flores;Michael Walsh.
Nature Genetics (2013)
Deficiencies in progenitor cells of multiple hematopoietic lineages and defective megakaryocytopoiesis in mice lacking the thrombopoietic receptor c-Mpl
Warren S. Alexander;Andrew W. Roberts;Nicos A. Nicola;Ruili Li.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: